A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression

PHASE2TerminatedINTERVENTIONAL
Enrollment

297

Participants

Timeline

Start Date

June 14, 2010

Primary Completion Date

September 12, 2011

Study Completion Date

September 12, 2011

Conditions
Major Depressive Disorder
Interventions
DRUG

CP-601,927

CP-601,927 1-2 mg twice per day, oral 1 mg tablets, for 6 weeks.

OTHER

Placebo

Matching placebo tablets, taken orally, twice per day, for 6 weeks.

Trial Locations (58)

10467

Montefiore Medical Center, The Bronx

11235

Social Psychiatry Research Institute, Brooklyn

11366

Comprehensive NeuroScience, Inc., Fresh Meadows

14215

Erie County Medical Center / State University of New York at Buffalo affiliate, Buffalo

18103

Lehigh Valley Health Network, Allentown

19004

City Line Family Medicine, Bala-Cynwyd

19063

Suburban Research Associates, Media

19104

University of Pennsylvania / Department of Psychiatry, Philadelphia

19136

Frankford Avenue Family Practice, PC, Philadelphia

22903

University of Virginia Health System / Department of Psychiatry and Neurobehavioral Sciences, Charlottesville

23219

Mcguire Hall Annex, Richmond

Nelson Clinic, Richmond

29201

Carolina Clinical Research Service LLC, Columbia

30308

Atlanta Center for Medical Research, Atlanta

30328

Atlanta Institute of Medicine and Research, Atlanta

32216

Clinical Neuroscience Solutions, Inc., Jacksonville

32751

Florida Clinical Research Center, LLC, Maitland

32806

Clinical Neuroscience Solutions, Inc., Orlando

33716

Comprehensive NeuroScience, Inc., St. Petersburg

43609

Kettlie Joseph Daniels, MD, Inc., Toledo

43623

Neurology and Neuroscience Center of Ohio, Toledo

45417

Midwest Clinical Research Center, Dayton

46260

Goldpoint Clinical Research, LLC, Indianapolis

47802

Clinco, Terre Haute

48307

Detroit Bio-Medical Laboratories, Inc., Rochester Hills

Rochester Center for Behavioral Medicine, Rochester Hills

53223

Northbrooke Research Center, Brown Deer

53562

Dean Foundation for Health, Research and Education, Middleton

60076

Psychiatric Medicine Associates, LLC., Skokie

60563

AMR-Baber Research Inc., Naperville

63301

St. Charles Psychiatric Associates - Midwest Research Group, Saint Charles

67207

Heartland Research Associates, LLC, Wichita

70114

Louisiana Research Associates, Inc., New Orleans

70629

Lake Charles Clinical Trials, Lake Charles

71115

Louisiana Clinical Research, LLC, Shreveport

72223

Arkansas Psychiatric Clinic Clinical Research Trials, P.A., Little Rock

73103

IPS Research, Oklahoma City

73116

Cutting Edge Research Group, Oklahoma City

75115

InSite Clinical Research, DeSoto

75231

FutureSearch Trials of Dallas, L.P., Dallas

75235

University of Texas (UT) Southwestern Medical Center at Dallas, Dallas

78731

FutureSearch Trials, Austin

80239

Radiant Research, Inc., Denver

84107

Radiant Research, Inc, Salt Lake City

84132

University of Utah School of Medicine Department of Psychiatry Mood Disorders Clinic, Salt Lake City

90210

Southwestern Research Incorporated, Beverly Hills

91950

Synergy Clinical Research Center, National City

92123

Artemis Institute for Clinical Research, San Diego

92845

Collaborative Neuroscience Network, Inc., Garden Grove

97210

Summit Research Network (Oregon), Inc., Portland

06360

Comprehensive Psychiatric Care, Norwich

William B. Backus Hospital Satellite Blood Draw, Norwich

02171

Massachusetts General Hospital, Boston

02721

AccelRx Research, Fall River

08002

Center for Emotional Fitness, Cherry Hill

02865

Lincoln Research, Lincoln

75390-9119

University of Texas (UT) Southwestern Medical Center at Dallas, Dallas

23298-0155

Virginia Commonwealth University (VCU) Medical Center, Richmond

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY